.. | ||
cdg-1a.molgen.TA | ||
cdg-1a.molgen.TB | ||
cdg-1a.T.metabolic_disorders_to_consider | ||
cdg-1a.T.metabolic_disorders_with_overla | ||
cdg-1a.T.molecular_genetic_testing_used | ||
cdg-1a.T.notable_pmm2_pathogenic_variant | ||
cdg-1a.T.pmm2cdg_frequency_of_select_fea | ||
cdg-1a.T.recommended_evaluations_followi | ||
cdg-1a.T.recommended_surveillance_for_in | ||
cdg-1a.T.treatment_of_manifestations_in |